Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)

• Published in: Chinese journal of integrative medicine 2010-02, Vol.16 (1), p.23-27
• Main Authors: Li, Li, Zhang, Xiao-jin, Lan, Yu, Xu, Le, Zhang, Xue-zhi, Wang, Hua-hong
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Alanine Transaminase - blood; Biomarkers - analysis; Biomarkers - blood; Capsules; Drugs, Chinese Herbal - administration & dosage; Drugs, Chinese Herbal - adverse effects; Fatty Liver - blood; Fatty Liver - diagnostic imaging; Fatty Liver - drug therapy; Female; Humans; Lipids - blood; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article; Tomography, X-Ray Computed; Treatment Outcome; Young Adult
• ISSN: 1672-0415; 1993-0402
• DOI: 10.1007/s11655-010-0023-1

Objective To observe the therapeutic effect and safety of Qianggan Capsule (强肝胶囊, QGC) in treating non-alcoholic fatty liver disease (NAFLD), using polyene phosphatidylcholine capsule (PPC) as a reference. Methods Eighty-eight patients with NAFLD were randomly assigned to two groups, 45 in the treatment group treated with QGC and 43 in the control group treated with PPC. The course of treatment lasted for 6 months. Changes in liver function, blood lipids, and iconographic indexes before and after treatment were observed, and clinical efficacy was evaluated. Results In the treatment group, alanine aminotransferase (ALT) was lowered significantly from 56.02±32.59 IU/L before treatment to 38.27±22.68 IU/L after treatment, and CT liver/spleen ratio significantly increased from 0.69±0.18 to 0.91±0.25, showing statistical significance ( P 0.05). No severe adverse reactions occurred during the whole treatment course. Conclusion QGC is an effective and safe remedy for the treatment of NAFLD.